Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL019 Phase IIIb in Pediatric/Young Adult ALL
NCT03123939Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Oct 2020
- Modality
- CAR-T Cells
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoint: Treatment-Emergent Adverse Events up to 12 months. Started Apr 2017; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03123939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123939.